Qualigen Therapeutics, Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 14, 2021 13:35 ET
|
Qualigen Therapeutics, Inc.
Conference call scheduled for May 18, 2021 at 4:10 p.m. EDT. Revenues Increased 30 Percent to $1.9 Million Compared to $1.5 Million in the Same Quarter of the Previous YearOn Track to File an IND...
Qualigen Therapeutics, Inc. to present at the Benzinga Biotech Small Cap Conference
March 18, 2021 08:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
Qualigen Therapeutics, Inc. Promotes Shishir Sinha to Chief Operating Officer Position
March 09, 2021 08:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference
March 08, 2021 08:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL
March 01, 2021 08:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL
March 01, 2021 08:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
Ritter Pharmaceuticals, Inc. Announces Expected Closing of Merger Transaction with Qualigen, Inc.
May 22, 2020 12:35 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 22, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), today announced that its pending merger transaction...
Ritter Pharmaceuticals, Inc. Announces Stockholder Approval of Proposals Required for Merger Transaction with Qualigen, Inc.
May 19, 2020 08:00 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 19, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), announced today that, based upon the final vote count...
Ritter Pharmaceuticals, Inc. Announces Adjournment of its Special Meeting
May 14, 2020 14:13 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 14, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter” or the “Company”), today announced that it has adjourned its special meeting of stockholders,...
Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued Listing
May 11, 2020 08:00 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 11, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that it has received written notice from the...